Table 1. The association of clinicopathological features and serum hsa-miR-423-5p expression in breast cancer.
| N(%) | has-miR-423-5p | |
| Age | ||
| ≤60 | 85 (75.4) | 2.93±0.62 |
| >60 | 28 (24.4) | 3.12±0.80 |
| Stage | ||
| I | 27 (24.1) | 2.55±0.89 |
| II | 56 (50) | 2.85±1.06 |
| III | 30 (26.9) | 3.22±0.92a |
| Grade | ||
| I | 26 (23.2) | 2.90±1.66 |
| II | 59 (52.2) | 2.68±1.23 |
| III | 28 (24.6) | 2.80±0.92 |
| Lymph Node | ||
| Negative | 31 (37.4) | 0.75±0.60 |
| Positive | 82 (72.6) | 1.37±0.45 |
| Estrogen receptor | ||
| Negative | 65 (57.1) | 0.44±0.32 |
| Positive | 48 (42.9) | 0.47±0.46 |
| Progesterone receptor | ||
| Negative | 66 (58.6) | 2.68±0.92 |
| Positive | 47 (41.4) | 2.97±1.18 |
| HER2/neu | ||
| Negative | 49 (43.8) | 3.02±0.87 |
| Positive | 64 (56.2) | 3.16±1.09 |
| Ki-67 | ||
| ≤14% | 46 (40.6) | 2.20±0.81 |
| >14% | 67 (59.4) | 3.47±0.76b |
Note: (a) P=0.001, (b) P=0.004, (c) No label indicates not significant.